Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc > market CRAZYNESS

<< Previous

Bullboard Posts

Next >>

Comment by bluemoons20on Jan 26, 2023 1:43pm

78 Views

Post# 35248237

RE:RE:market CRAZYNESS

Yes, Probably is in relation to the PP they probably cannot be too far below price it has traded at for a number of days.

And still crazy since we just had a PP and now another with proceeds as general operating capital??

This just keeps getting worse when the arbitration conclusion is so close??

GLTA

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario